Your browser doesn't support javascript.
Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study.
Averbuch, Dina; de la Camara, Rafael; Tridello, Gloria; Knelange, Nina Simone; Bykova, Tatiana A; Ifversen, Marianne; Dobsinska, Veronika; Ayas, Mouhab; Hamidieh, Amir Ali; Pichler, Herbert; Perez-Martinez, Antonio; Cesaro, Simone; Sundin, Mikael; Badell, Isabel; Bader, Peter; Johansson, Jan-Erik; Mirci-Danicar, Oana; Sedlacek, Petr; Paillard, Catherine; Gibson, Brenda; Lawson, Sarah; Kroeger, Nicolaus; Corbacioglu, Selim; Mikulska, Malgorzata; Piñana, Jose Luis; Styczynski, Jan; Ljungman, Per.
  • Averbuch D; Faculty of Medicine, Hebrew University of Jerusalem, Pediatric Infectious Diseases, Hadassah Medical Center, Jerusalem, Israel. adiana@hadassah.org.il.
  • de la Camara R; Hematology Department, Hospital Universitario de La Princesa, Madrid, Spain.
  • Tridello G; Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Knelange NS; EBMT - Leiden Study Unit, Leiden, Netherlands.
  • Bykova TA; RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia.
  • Ifversen M; Department of Children and Adolescents Medicine, Stem Cell Transplant Unit, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Dobsinska V; Department of Pediatric Hematology and Oncology, Comenius University, Bratislava, Slovakia.
  • Ayas M; Bone Marrow Transplantation Unit, National Institute of Children's Diseases, Bratislava, Slovakia.
  • Hamidieh AA; Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
  • Pichler H; Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Perez-Martinez A; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Cesaro S; Department of Pediatric Hematology and Oncology, Hospital Universitario La Paz, Madrid, Spain.
  • Sundin M; Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Badell I; Section of Pediatric Hematology, Immunology and HCT, Astrid Lindgren Children's Hospital, Karolinska University Hospital and Division of Pediatrics, CLINTEC, Karolinska Institutet, Stockholm, Sweden.
  • Bader P; Pediatric BMT Unit, Hospital Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Johansson JE; Universitaetsklinikum Frankfurt Goethe-Universitaet, Frankfurt Main, Germany.
  • Mirci-Danicar O; Sahlgrenska University Hospital, Goeteborg, Sweden.
  • Sedlacek P; BMT Unit, Bristol Royal Hospital for Children, Bristol, UK.
  • Paillard C; HSCT Unit, Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic.
  • Gibson B; Pediatric Hematology Oncology, Hautepierre Hospital, Strasbourg University, Strasbourg, France.
  • Lawson S; Department of Haematology, Royal Hospital for Children, Glasgow, UK.
  • Kroeger N; Department of Haematology, Birmingham Children's Hospital, Birmingham, UK.
  • Corbacioglu S; Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
  • Mikulska M; Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.
  • Piñana JL; Division of Infectious Diseases, University of Genova, Ospedale Policlinco San Martino, Genova, Italy.
  • Styczynski J; Hospital Clinico Universitario de Valencia. Fundación de investigación INCLIVA, Hospital Clinico Universitario de Valencia, Valencia, Spain.
  • Ljungman P; Pediatric Hematology and Oncology, University Hospital, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
Bone Marrow Transplant ; 58(5): 558-566, 2023 05.
Article in English | MEDLINE | ID: covidwho-2250581
ABSTRACT
Risk factors for severe SARS-Cov-2 infection course are poorly described in children following hematopoietic cell transplantation (HCT). In this international study, we analyzed factors associated with a severe course (intensive care unit (ICU) admission and/or mortality) in post-HCT children. Eighty-nine children (58% male; median age 9 years (min-max 1-18)) who received an allogeneic (85; 96%) or an autologous (4; 4%) HCT were reported from 28 centers (18 countries). Median time from HCT to SARS-Cov-2 infection was 7 months (min-max 0-181). The most common clinical manifestations included fever (37; 42%) and cough (26; 29%); 37 (42%) were asymptomatic. Nine (10%) children following allo-HCT required ICU care. Seven children (8%) following allo-HCT, died at a median of 22 days after SARS-Cov-2 diagnosis. In a univariate analysis, the probability of a severe disease course was higher in allo-HCT children with chronic GVHD, non-malignant disease, immune suppressive treatment (specifically, mycophenolate), moderate immunodeficiency score, low Lansky score, fever, cough, coinfection, pulmonary radiological findings, and high C-reactive protein. In conclusion, SARS-Cov-2 infection in children following HCT was frequently asymptomatic. Despite this, 10% needed ICU admission and 8% died in our cohort. Certain HCT, underlying disease, and SARS-Cov-2 related factors were associated with a severe disease course.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Communicable Diseases / Hematopoietic Stem Cell Transplantation / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Variants Limits: Child / Female / Humans / Male Language: English Journal: Bone Marrow Transplant Journal subject: Transplantation Year: 2023 Document Type: Article Affiliation country: S41409-023-01941-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Communicable Diseases / Hematopoietic Stem Cell Transplantation / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Variants Limits: Child / Female / Humans / Male Language: English Journal: Bone Marrow Transplant Journal subject: Transplantation Year: 2023 Document Type: Article Affiliation country: S41409-023-01941-5